| 3.92 0.72 (22.5%) | 08-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 5.43 |
1-year : | 6.34 |
| Resists | First : | 4.65 |
Second : | 5.43 |
| Pivot price | 2.55 |
|||
| Supports | First : | 2.93 |
Second : | 1.87 |
| MAs | MA(5) : | 2.65 |
MA(20) : | 2.67 |
| MA(100) : | 5.95 |
MA(250) : | 76.9 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 48 |
D(3) : | 25 |
| RSI | RSI(14): 64.6 |
|||
| 52-week | High : | 303.25 | Low : | 1.87 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ RSLS ] has closed above the upper band by 23.6%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 75.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 78 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.66 - 4.68 | 4.68 - 4.7 |
| Low: | 2.77 - 2.78 | 2.78 - 2.8 |
| Close: | 3.89 - 3.92 | 3.92 - 3.95 |
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.
Wed, 13 Aug 2025
Clinical-Stage Vyome Targets $100B Inflammation Market Through Nasdaq Merger with ReShape - Stock Titan
Wed, 13 Aug 2025
ReShape Lifesciences Stock Rocketed 61% Today – Here’s Why - Stocktwits
Thu, 07 Aug 2025
ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics - Business Wire
Thu, 12 Jun 2025
ReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets - Yahoo Finance
Mon, 09 Jun 2025
ReShape Lifesciences® Announces Pricing of $2.6 Million Public Offering - GlobeNewswire
Mon, 09 Jun 2025
Why Is ReShape Lifesciences Stock (RSLS) Down 45% Today? - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 10.6 (%) |
| Held by Institutions | 1.3 (%) |
| Shares Short | 52 (K) |
| Shares Short P.Month | 52 (K) |
| EPS | -830.45 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -8.66 |
| Profit Margin | -48.3 % |
| Operating Margin | -165.3 % |
| Return on Assets (ttm) | -53.5 % |
| Return on Equity (ttm) | -120.2 % |
| Qtrly Rev. Growth | -42.8 % |
| Gross Profit (p.s.) | 1.91 |
| Sales Per Share | 3 |
| EBITDA (p.s.) | -2.63 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -0.46 |
| Price to Sales | 1.3 |
| Price to Cash Flow | -2.1 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|